Our study highlights the therapeutic potential of canagliflozin in septic AKI, emphasizing its role in preserving mitochondrial function and promoting tubular cell survival through the AMPKα1/PGC1α/NRF1 axis. This evidence concerns the gene PPARGC1A and acute kidney injury.